FOMAT
MEDICAL RESEARCH

Proud Parter Of
hyperCORE
INTERNATIONAL
RESEARCH ACCELERATED

Why is Diversity Essential to Our Organization?

A vast majority of Clinical Trial (CT) participants generally identify as Caucasian. This means that treatment protocols and screening practices usually form around the data received from this population which may not be suitable when a new medical product/treatment intends to enter into a diverse population.

According to the CDC, diabetes, CVD, chronic liver and kidney diseases are more prevalent in the Hispanic and Latino population than in Caucasians. Lifestyle habits (which vary between cultures) also play a role that impacts an individual's health and healthcare as a whole. Therefore, at FOMAT, we are committed to diversifying CTs to provide the most accurate clinical data to benefit a diverse population.

How Are We Overcoming Challenges of Diversity?

We focus on advanced recruiting efforts that target diverse patient populations. Our efforts include creating marketing campaigns to reach a diverse audience while keeping language and cultural differences in mind. Through our Community Educational Outreach Program, we also work towards reaching out to minority populations within the community that is often underserved and underrepresented.

Diversity with FOMAT

At FOMAT, we aim to innovate healthcare through diversity by focusing our recruitment efforts to ensure a diverse patient population within our clinical trials.

We were nominated as the top 3 finalists for the SPRIA Award in 2022.

	FOMAT Enrollment	US Patient	US Census (2019)
White/ Caucasian	✓ 30.2%	72.6%	60.1%
Black /African American	– 2.13%	6.9%	13.4%
Hispanic or Latino	✓ 51.5%	9.2%	18.5%
Asian	✓ 7.3%	3.4%	5.9%
Native Hawaiian or Pacific Islander	✓ 1%	0.1%	0.2%
Native Indian or Native Alaskan	✓ 0.4%	0.1%	1.3%
More than 1 race	✓ 0.3%	0.0%	2.7%
Other or Unknown	✓ 6.8%	3.7%	-

Source: FDA, United States Census Bureau & FOMAT data from 2022

How Do We Track Diversity?

We track diversity categorizing through our databases, as well our CTMS System, following the FDA guidelines.

Brandon Johnson
Business Development Specialist

bd@fomatmedical.com
fomatmedical.com